Search

Your search keyword '"CANCER ALPHA(V)-INTEGRIN EXPRESSION"' showing total 2 results
Start Over Descriptor "CANCER ALPHA(V)-INTEGRIN EXPRESSION"
2 results on '"CANCER ALPHA(V)-INTEGRIN EXPRESSION"'

1. RGD-based strategies for selective delivery of therapeutics and imaging agents to the tumour vasculature

Subjects
CONDITIONALLY REPLICATIVE ADENOVIRUSES, RGD, therapeutic proteins, cytostatic drugs, ARG-GLY-ASP, NECROSIS-FACTOR-ALPHA, radiotracer, endothelial cells, angiogenesis, POSITRON-EMISSION-TOMOGRAPHY, VIRUS-LIKE PARTICLES, drug delivery, SNAKE-VENOM DISINTEGRINS, Arg-Gly-Asp, antivascular therapies, cancer, gene delivery, VITRONECTIN RECEPTOR ANTAGONIST, POTENT ANTITUMOR-ACTIVITY, CANCER ALPHA(V)-INTEGRIN EXPRESSION, polymers, ALPHA(V)BETA(3) INTEGRIN ANTAGONISTS
Abstract

During the past decade, RGD-peptides have become a popular tool for the targeting of drugs and imaging agents to a(v)beta(3)-integrin expressing tumour vasculature. RGD-peptides have been introduced by recombinant means into therapeutic proteins and viruses. Chemical means have been applied to couple RGD-peptides and RGD-mimetics to liposomes, polymers, peptides, small molecule drugs and radiotracers. Some of these products show impressive results in preclinical animal models and a RGD targeted radiotracer has already successfully been tested in humans for the visualization Of alpha(v)beta(3)-integrin, which demonstrates the feasibility of this approach.This review will summarize the structural requirements for RGD-peptides and RGD-mimetics as ligands for alpha(v)beta(3). We will show how they have been introduced in the various types of constructs by chemical and recombinant techniques. The importance of multivalent RGD-constructs for high affinity binding and internalization will be highlighted. Furthermore the in vitro and in vivo efficacy of RGD-targeted therapeutics and diagnostics reported in recent years will be reviewed. (C) 2005 Elsevier Ltd. All rights reserved.

Published
2005
Full Text
View/download PDF

2. RGD-based strategies for selective delivery of therapeutics and imaging agents to the tumour vasculature

Author

Temming, Kai, Schiffelers, Raymond M., Molema, Grietje, Kok, Robbert J., Sub Drug targeting, Sub Drug delivery, Pharmaceutics, Sub Drug targeting, Sub Drug delivery, and Pharmaceutics

Subjects
CONDITIONALLY REPLICATIVE ADENOVIRUSES, Vascular Endothelial Growth Factor A, Cancer Research, Polymers, Endothelial cells, Therapeutic proteins, Cilengitide, protein binding, Pharmacology, gene targeting, Polyethylene Glycols, chemistry.chemical_compound, paclitaxel, cytarabine, drug binding, rgd10 peptide, Neoplasms, Arg-Gly-Asp, drug delivery system, Pharmacology (medical), Gene delivery, VITRONECTIN RECEPTOR ANTAGONIST, POTENT ANTITUMOR-ACTIVITY, RNA, Small Interfering, Internalization, virus replication, media_common, Cancer, Clinical Trials as Topic, Drug Carriers, RGD, Antivascular therapies, clinical trial, Small molecule, Recombinant Proteins, unclassified drug, Infectious Diseases, Oncology, priority journal, Drug delivery, Oligopeptides, media_common.quotation_subject, ligand binding, Genetic Vectors, review, Antineoplastic Agents, Computational biology, Biology, Transfection, doxorubicin, Peptides, Cyclic, Adenoviridae, POSITRON-EMISSION-TOMOGRAPHY, tumor vascularization, VIRUS-LIKE PARTICLES, In vivo, SNAKE-VENOM DISINTEGRINS, Animals, Humans, human, drug accumulation, arginylglycylaspartic acid, Radiotracer, Tumor Necrosis Factor-alpha, NECROSIS-FACTOR-ALPHA, Endothelial Cells, drug targeting, Genetic Therapy, Integrin alphaVbeta3, heterozygote, amino acid sequence, drug structure, chemistry, Targeted drug delivery, cilengitide, Doxorubicin, Mutation, drug synthesis, Cytostatic drugs, Angiogenesis, CANCER ALPHA(V)-INTEGRIN EXPRESSION, ALPHA(V)BETA(3) INTEGRIN ANTAGONISTS, Arginylglycylaspartic acid
Abstract

During the past decade, RGD-peptides have become a popular tool for the targeting of drugs and imaging agents to a(v)beta(3)-integrin expressing tumour vasculature. RGD-peptides have been introduced by recombinant means into therapeutic proteins and viruses. Chemical means have been applied to couple RGD-peptides and RGD-mimetics to liposomes, polymers, peptides, small molecule drugs and radiotracers. Some of these products show impressive results in preclinical animal models and a RGD targeted radiotracer has already successfully been tested in humans for the visualization Of alpha(v)beta(3)-integrin, which demonstrates the feasibility of this approach. This review will summarize the structural requirements for RGD-peptides and RGD-mimetics as ligands for alpha(v)beta(3). We will show how they have been introduced in the various types of constructs by chemical and recombinant techniques. The importance of multivalent RGD-constructs for high affinity binding and internalization will be highlighted. Furthermore the in vitro and in vivo efficacy of RGD-targeted therapeutics and diagnostics reported in recent years will be reviewed. (C) 2005 Elsevier Ltd. All rights reserved.

Published
2005

Catalog

Books, media, physical & digital resources
See catalog results